TC BioPharm is a world-leading immunotherapy company that has seen positive results in its latest clinical cancer trial. They are now looking to advance those trials as well as extend their IP protected technology to a COVID-19 therapy, having recently received regulatory approval for a Phase I trial.
Immunotherapy is one of the most important innovations in healthcare to emerge in the last 20 years. It is a form of treatment that uses the body's own immune system to prevent cancer and infectious disease. Using patented technology, TC BioPharm harnesses the power of a particular part of the immune system, gamma delta T-cells (GDT), with encouraging results.
Cancer trial success
We have treated terminally ill patients with acute myeloid leukaemia in approved clinical trials. Initial results are very encouraging and with positive responses in multiple patients. There were no material side effects.
Immunotherapies are, in many cases, very expensive treatments. Using our GDT technology could enable us to provide a much lower cost solution, making it more widely accessible to patients.
Supported by recent clinical evidence, we are delighted to have received regulatory approval from the MHRA to run a COVID-19 clinical trial to address the global pandemic. In addition, we will advance our current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally.
Series A funding round
We have already raised over £7m in the last 15 months and are seeking to raise additional investment to take our clinical trials forward in COVID-19 and cancer.